Wave Life Sciences Ltd (NASDAQ:WVE) – Equities researchers at Leerink Swann boosted their Q1 2018 earnings per share (EPS) estimates for Wave Life Sciences in a research report issued to clients and investors on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the company will post earnings per share of ($0.11) for the quarter, up from their previous forecast of ($1.10). Leerink Swann currently has a “Outperform” rating and a $64.00 target price on the stock. Leerink Swann also issued estimates for Wave Life Sciences’ Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.27) EPS, FY2018 earnings at ($0.73) EPS and FY2019 earnings at ($4.16) EPS.
A number of other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. BidaskClub upgraded Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 2nd. Mizuho set a $34.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a research note on Tuesday. Finally, TheStreet upgraded Wave Life Sciences from a “d+” rating to a “c-” rating in a research note on Friday, January 5th. Two analysts have rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $44.50.
Shares of Wave Life Sciences (NASDAQ:WVE) opened at $50.60 on Friday. Wave Life Sciences has a 12 month low of $15.15 and a 12 month high of $55.95. The company has a quick ratio of 11.50, a current ratio of 11.50 and a debt-to-equity ratio of 0.01.
In other Wave Life Sciences news, insider Michael A. Panzara sold 511 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $52.10, for a total transaction of $26,623.10. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Chris Francis sold 21,639 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $55.40, for a total value of $1,198,800.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,466 shares of company stock worth $1,321,808. 53.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new position in Wave Life Sciences during the 4th quarter worth approximately $222,000. Nationwide Fund Advisors lifted its holdings in Wave Life Sciences by 58.1% during the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Wave Life Sciences in the 4th quarter worth approximately $316,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Wave Life Sciences by 71.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after purchasing an additional 3,912 shares during the last quarter. Finally, Alliancebernstein L.P. bought a new stake in shares of Wave Life Sciences in the 2nd quarter worth approximately $236,000. 74.27% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Q1 2018 EPS Estimates for Wave Life Sciences Ltd Increased by Leerink Swann (WVE)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/23/q1-2018-eps-estimates-for-wave-life-sciences-ltd-increased-by-leerink-swann-wve.html.
Wave Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.